Two Canadian studies are shedding light on the high number of patients across Canada who are suffering in silence because of ...

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...